KUALA LUMPUR: Malaysian Genomics Resource Centre Berhad (MGRC) and its subsidiary Clinipath Sdn Bhd yesterday announced the availability of Dtect Prostate+ service, an affordable genetic test that examines key genes associated with prostate cancer.
MGRC in a statement here yesterday said positive results from Dtect Prostate+ may identify a need for regular, pathology surveillance to catch the disease early when it is easiest to treat and may also useful to encourage positive lifestyle changes to mitigate the risk of prostate cancer occurring.
Genetic screening can identify genetic predispositions to prostate cancer, said the statement.
The statement said that in 2018, the Ministry of Health published the MySCan study on cancer and survival rates which one of the findings was that early detection and treatment of prostate cancer (at Stage 1) led to a five-year relative survival rate of 97.3 per cent.
MGRC and Clinipath continue to work together to make comprehensive pathology services, and the latest in genetic testing available to doctors with a view to improving the lives of patients in Malaysia and the region.
MGRC, a public-listed healthcare company, was a pioneer in genome sequencing, bioinformatics analysis and genetic screening services and today the company is focused on merging the latest genetic testing with pathology to enable doctors to provide personalised healthcare for their patients. – Bernama
